Breaking News, Collaborations & Alliances

Oxford Genetics & ERS Genomics Extend Agreement

Their pre-existing non-exclusive, license agreement now includes the use of CRISPR gene editing technology in the APAC region

Oxford Genetics and ERS Genomics have extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific (APAC) region, to support the company’s international growth following demand for the service quadrupling in 2018. Oxford Genetics has already seen its sales of non-CRISPR related product...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters